MDT · News · 20260915N

Diabetes Business Separation

Medtronic plc · 2026-09-15 · Importance 46 · Surprise 42

Medtronic launched an exchange offer to separate its diabetes business, MiniMed, into an independent company. Chief Executive Officer Geoff Martha cited MiniMed’s results, innovation pipeline, and market position as reasons for the separation. Medtronic expects the transaction to allow greater capital focus on its cardiovascular, neuroscience, and surgical portfolios, while MiniMed operates as a standalone diabetes-technology company.